

# Indoco Remedies Receives USFDA Final Approval for Lacosamide Oral Solution Generic

1 min read Updated on 30 Jan 2026, 01:28 PM  
Reviewed by: Ashish T | ScanX News Team

## Overview

Indoco Remedies has received final USFDA approval for Lacosamide Oral Solution, 10 mg/ml, allowing the company to market a generic version of Vimpat Oral Solution in the US market. This regulatory milestone strengthens the company's US pharmaceutical portfolio and provides potential cost-effective treatment alternatives for patients requiring antiepileptic medication.



Indoco Remedies has achieved a significant regulatory milestone with the receipt of final approval from the United States Food and Drug Administration (USFDA) for its Lacosamide Oral Solution, 10 mg/ml. This approval enables the pharmaceutical company to manufacture and commercialize a generic version of Vimpat Oral Solution, 10 mg/ml, in the competitive US market.

## Regulatory Approval Details

The USFDA final approval grants Indoco Remedies the authorization to launch its generic formulation of Lacosamide Oral Solution with a concentration of 10 mg/ml. This generic product will serve as an alternative to the branded Vimpat Oral Solution, 10 mg/ml, potentially offering cost-effective treatment options for patients.

Parameter:	Details
Product:	Lacosamide Oral Solution
Concentration:	10 mg/ml
Regulatory Status:	USFDA Final Approval
Reference Product:	Vimpat Oral Solution, 10 mg/ml
Market:	United States

## Market Implications

The approval strengthens Indoco Remedies' presence in the US pharmaceutical market and adds to its generic drug portfolio. Lacosamide is typically used as an antiepileptic medication, and the availability of a generic version may provide healthcare providers and patients with additional treatment options.

## Strategic Significance

This USFDA approval represents an important development for Indoco Remedies' international expansion strategy. The company's ability to secure regulatory clearance for generic formulations in the US market demonstrates its manufacturing capabilities and regulatory compliance standards. The approval allows the company to participate in the generic pharmaceutical segment for this specific therapeutic area.

### Historical Stock Returns for Indoco Remedies

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+2.16%	+0.83%	-3.71%	-31.93%	-12.45%	-27.63%